| Description | Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that humanizes the extracellular SRCR distal domain 1 of CD6. Itolizumab slows T cell proliferation and inhibits the production of pro-inflammatory cytokines. Itolizumab can be used to study conditions as diverse as psoriasis, rheumatoid arthritis (RA) and COVID-19 disease. |
| In vitro | Itolizumab在100 μg/mL浓度下可抑制T细胞增殖[1]。在PBMCs中，0-100 μg/mL的Itolizumab能够抑制Treg向极性的转变并增强Th1表型的获得[1]。在PBMCs过夜培养过程中，40 μg/mL的Itolizumab能够减少CD26hiCD161+ CD8+ T细胞的数量[2]。在Th17极化条件下刺激的PBMCs中，40 μg/mL的Itolizumab在3-12天内能够降低IL-17和IFN-γ的表达[3]。 |
| In vivo | 在人源化异种移植小鼠模型中，用于研究移植物抗宿主病（GVHD）的情况下，通过腹膜内给药，Itolizumab在每日剂量为60μg或300μg时显示出治疗效果[4]。 |
| Synonyms | EQ-001 |
| molecular weight | N/A |
| CAS | 1116433-11-4 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Freitas RF, et al. Modulation of CD4 T cell function via CD6-targeting. EBioMedicine. 2019 Sep;47:427-435. [Content Brief] 2. Globig AM, et al. High-dimensional profiling reveals Tc17 cell enrichment in active Crohn's disease and identifies a potentially targetable signature. Nat Commun. 2022 Jun 27;13(1):3688. 3. Bughani U, et al. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS One. 2017 Jul 3;12(7):e0180088. 4. Cherie Tracy Ng, et al. Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease. Blood (2019) 134 (Supplement_1): 5603. |